Clinical Trial

Hantaan Puumala Virus DNA Vaccine

Study Description

A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine

This is a single-center, randomized, single-blinded study of the Hantaan virus HTNV DNA vaccine alone, Puumala virus PUUV DNA vaccine alone, and mixed Hantaan/Puumala HTNV/PUUV DNA vaccines delivered intramuscularly IM by the needle-free PharmaJet Stratus DSJI device.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - Hantaan Vaccine:

DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

Biological - Puumala Vaccine

DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

Biological - Hantaan/Puumala Vaccine

DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

Additional Information

Official Study Title

Hantaan Virus Plasmid DNA (Expressing Gn and Gc Antigens; E. Coli; Althea Technologies, Inc.) Vaccine Hantaan [HTNV-DNA Vaccine] and Puumala Virus DNA (Expressing Gn and Gc Antigens; E. Coli; Althea Technologies, Inc.) Vaccine Puumala [PUUV-DNA Vaccine] Administered Via Stratus Needle-free Injection System (PharmaJet, Inc.)

Clinical Trial ID

NCT02776761

ParticipAid ID

ZdPKAb